Pfizer Presents Positive Phase 2 Data in Alopecia Areata During LateBreaker Session at the 27th European Academy of Dermatology and Venereology EADV Congress

Pfizer Inc. NYSEPFE today announced results from its Phase 2a study of PF06651600 an oral Janus kinase JAK 3 inhibitor and PF06700841 a tyrosine kinase TYK 2JAK1 inhibitor compared to placebo in patients with moderate to severe alop...